[go: up one dir, main page]

IL106776A0 - Use of a kallikrein inhibitor for the production of a pharmaceutical for the prophylaxis and therapy of certain diseases - Google Patents

Use of a kallikrein inhibitor for the production of a pharmaceutical for the prophylaxis and therapy of certain diseases

Info

Publication number
IL106776A0
IL106776A0 IL106776A IL10677693A IL106776A0 IL 106776 A0 IL106776 A0 IL 106776A0 IL 106776 A IL106776 A IL 106776A IL 10677693 A IL10677693 A IL 10677693A IL 106776 A0 IL106776 A0 IL 106776A0
Authority
IL
Israel
Prior art keywords
prophylaxis
therapy
pharmaceutical
production
certain diseases
Prior art date
Application number
IL106776A
Other languages
English (en)
Original Assignee
Behringwerke Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Behringwerke Ag filed Critical Behringwerke Ag
Publication of IL106776A0 publication Critical patent/IL106776A0/xx

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/55—Protease inhibitors
    • A61K38/57—Protease inhibitors from animals; from humans
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A61K9/0029—Parenteral nutrition; Parenteral nutrition compositions as drug carriers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
    • Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10S530/00—Chemistry: natural resins or derivatives; peptides or proteins; lignins or reaction products thereof
    • Y10S530/827—Proteins from mammals or birds
    • Y10S530/829—Blood
    • Y10S530/83—Plasma; serum

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Immunology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Zoology (AREA)
  • Dermatology (AREA)
  • Nutrition Science (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Rheumatology (AREA)
  • Cardiology (AREA)
  • Pain & Pain Management (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Physiology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
IL106776A 1992-08-24 1993-08-23 Use of a kallikrein inhibitor for the production of a pharmaceutical for the prophylaxis and therapy of certain diseases IL106776A0 (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
DE4227762A DE4227762A1 (de) 1992-08-24 1992-08-24 Verwendung eines Kallikrein-Inhibitors zur Herstellung eines Arzneimittels zur Prophylaxe und Therapie bestimmter Krankheiten

Publications (1)

Publication Number Publication Date
IL106776A0 true IL106776A0 (en) 1993-12-08

Family

ID=6466096

Family Applications (1)

Application Number Title Priority Date Filing Date
IL106776A IL106776A0 (en) 1992-08-24 1993-08-23 Use of a kallikrein inhibitor for the production of a pharmaceutical for the prophylaxis and therapy of certain diseases

Country Status (9)

Country Link
US (1) US5939389A (no)
EP (1) EP0586909A3 (no)
JP (1) JPH06157343A (no)
KR (1) KR100290753B1 (no)
AU (1) AU671287B2 (no)
CA (1) CA2104636C (no)
DE (2) DE4244735A1 (no)
IL (1) IL106776A0 (no)
NO (1) NO933000L (no)

Families Citing this family (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE4244735A1 (de) * 1992-08-24 1994-03-31 Behringwerke Ag Verwendung von C1-Inaktivator zur Bekämpfung von Komplikationen bei der Anwendung von Zytokinen, endogenen Mediatoren, gentechnisch produzierten Mediator-Hybriden oder Wachstumsfaktoren im Rahmen der therapeutischen Anwendung dieser Substanzen
JP2000507204A (ja) * 1995-12-18 2000-06-13 ステイヒテイング・サンキン・ブロードボールジーニング Ｃ１―インヒビターの補体及び血液凝固阻害特性の強化
DE19827750C1 (de) 1998-06-22 1999-07-29 Centeon Pharma Gmbh Verfahren zum Abtrennen von HIV aus einer Flüssigkeit
US20040152635A1 (en) * 1998-06-22 2004-08-05 Albrecht Groner Modified C1 esterase inhibitor for blocking the infectiousness of HIV
AU2006203549B2 (en) * 2000-01-31 2008-10-09 Pharming Intellectual Property B.V. C1 inhibitor produced in the milk of transgenic mammals
DK1252184T3 (da) * 2000-01-31 2008-02-04 Pharming Intellectual Pty Bv Human C1-inhibitor produceret i mælk af transgene dyr
US7067713B2 (en) 2000-01-31 2006-06-27 Pharming Intellectual Property B.V. C1 Inhibitor produced in the milk of transgenic non-human mammals
PL1626736T3 (pl) 2003-05-16 2021-05-04 Pharming Intellectual Property B.V. Inhibitor c1 o krótkim okresie półtrwania do leczenia przejściowego
DK2698166T3 (en) 2006-10-10 2015-12-21 Regenesance B V KOMPLEMENTÆRHÆMNING FOR BETTER nerves GENERATION
CN104010656B (zh) 2011-09-24 2016-02-24 德国杰特贝林生物制品有限公司 使用免疫球蛋白和c1-抑制剂的联合疗法
CN104080474B (zh) 2011-12-22 2016-04-27 德国杰特贝林生物制品有限公司 C1-抑制剂在治疗中枢神经系统继发性水肿中的应用
US10441631B2 (en) 2013-02-28 2019-10-15 Csl Behring Gmbh Therapeutic agent for amniotic fluid embolism
WO2014135694A1 (en) 2013-03-08 2014-09-12 Csl Behring Ag Treatment and prevention of remote ischemia-reperfusion injury
WO2014207199A1 (en) 2013-06-28 2014-12-31 Csl Behring Gmbh Combination therapy using a factor xii inhibitor and a c1-inhibitor
WO2016196070A1 (en) 2015-06-03 2016-12-08 Children's Hospital Medical Center Compositions and methods for treating neonatal biliary atresia
EP3493832A1 (en) 2016-08-05 2019-06-12 CSL Behring GmbH Pharmaceutical formulations of c1 esterase inhibitor
US20190183991A1 (en) 2016-08-23 2019-06-20 Csl Behring Gmbh Method of preventing acute attacks of hereditary angioedema associated with c1 esterase inhibitor deficiency
EP3681517B1 (en) 2017-09-15 2024-05-08 Cedars-Sinai Medical Center C1 esterase inhibitors for use in improving organ function in organ transplant patients
KR20230110563A (ko) 2020-11-20 2023-07-24 체에스엘 베링 게엠베하 항체 매개 거부 반응의 치료 방법

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE3228502A1 (de) * 1982-07-30 1984-02-02 Behringwerke Ag, 3550 Marburg Verfahren zur herstellung des c1-inaktivators und seine verwendung
US5271931A (en) * 1988-09-14 1993-12-21 The Scripps Research Institute Methods for increasing C1 inhibitor concentrations using interferon-gamma and/or interleukin-6
US5030578A (en) * 1989-07-10 1991-07-09 The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services Process for the purification of C1-inhibitor
DK0512090T4 (da) * 1990-10-16 2007-01-15 Sonoran Desert Chemicals Llc Behandling af inflammation
WO1992022320A1 (en) * 1991-06-14 1992-12-23 Genentech, Inc. C1 inhibitor variants and treating inflammatory response with c1 inhibitor
DE4227735C2 (de) * 1992-08-21 1995-10-12 Leybold Ag Anordnung zum berührungslosen Messen der Dicke von Schichten
DE4244735A1 (de) * 1992-08-24 1994-03-31 Behringwerke Ag Verwendung von C1-Inaktivator zur Bekämpfung von Komplikationen bei der Anwendung von Zytokinen, endogenen Mediatoren, gentechnisch produzierten Mediator-Hybriden oder Wachstumsfaktoren im Rahmen der therapeutischen Anwendung dieser Substanzen

Also Published As

Publication number Publication date
NO933000D0 (no) 1993-08-23
DE4227762A1 (de) 1994-03-03
KR100290753B1 (ko) 2001-09-17
JPH06157343A (ja) 1994-06-03
CA2104636A1 (en) 1994-02-25
KR940003564A (ko) 1994-03-12
AU671287B2 (en) 1996-08-22
NO933000L (no) 1994-02-25
EP0586909A3 (de) 1995-04-05
CA2104636C (en) 2003-11-11
AU4477893A (en) 1994-03-03
US5939389A (en) 1999-08-17
DE4244735A1 (de) 1994-03-31
EP0586909A2 (de) 1994-03-16

Similar Documents

Publication Publication Date Title
IL106776A0 (en) Use of a kallikrein inhibitor for the production of a pharmaceutical for the prophylaxis and therapy of certain diseases
IL104324A0 (en) Variant of human kunitz-type protease inhibitor
TW272940B (en) /
HU9303218D0 (en) Application of atp-depended protease and its inhibitor for treatment of cachexy and amyotrophia
FI956227L (fi) Sisäänhengitykseen tarkoitettu terapeuttinen valmiste
IL105521A0 (en) The use of inhibitors of plasminogen activators for the treatment of inflammations and wounds
FI943231L (fi) Ihmisen Kunitz-tyyppisen proteaasiestäjän muunnoksia
EP0575749A3 (en) Use of potassium-channel activators for the manufacture of a medicament for the treatment of gastrointertinal ulcers
AU7269294A (en) Use of glucokinase inhibitors for the manufacture of a medicament for treating tumours
GB9226832D0 (en) Pharmaceutical preparations for the treatment of psoriasis
AU1567588A (en) A pharmaceutical combination for the prophylaxis and therapy of malaria
IL119459A0 (en) Pharmaceutical agents for the treatment of acute and chronic inflammatory diseases
AU2807492A (en) Use of misoprostol for the treatment of allergy
AU1116895A (en) Use of theophylline for the manufacture of a medicament for the treatment of asthma
EP0765661A3 (en) Use of docosahexaenoic acid for the manufacture of a medicament for the treatment of glumerulonephritis
HU9203496D0 (en) Aza-benzimidazoles applicqbles for treatment of asthma, arthritis and similqr diseases
FI950725A7 (fi) Trisyklisen yhdisteen käyttö muistin ja tajunnan häiriöiden hoitoon tarkoitettujen lääkevalmisteiden valmistukseen
EP0689839A3 (en) Use of adenosine triphosphatase inhibitors for the manufacture of a medicament for the treatment of beta-amyloid peptide-associated disorders
AU2299592A (en) Treatment of periodontal disease with protease inhibitors
ZA936707B (en) Use of a direct-acting thrombin inhibitor for the manufacture of a medicinal product having thrombolytic activity
IL106751A0 (en) Pharmaceutical compositions for the treatment of reversible obstructive airways diseases
ZA95908B (en) A synergistic formulation for treatment of rheumatic diseases
IL109235A0 (en) Pharmaceutical compositions containing ureido derivatives for the treatment of lentivirus-induced diseases
ZA944671B (en) Medicaments for the treatment of inflammatory diseases
HUP0104619A3 (en) Use of pde inhibitors in the manufacture of a medicament for the treatment of bladder diseases